文献速递银屑病与炎症性皮肤病

抑制SIK2/SIK3可减轻银屑病炎症特征

Inhibition of salt-inducible kinases 2 and 3 reduces inflammatory signature in psoriasis.
PubMed 文献 · J Invest Dermatol · 2026-08-18

本研究探讨SIK2/SIK3抑制剂GLPG3970在银屑病中起效的分子机制。空间转录组和单细胞测序显示银屑病皮损中SIK2和SIK3高表达而SIK1不表达;体外GLPG3970可降低外周单个核细胞、T细胞和成纤维细胞中的银屑病标志细胞因子和趋化因子,但对角质形成细胞无此作用;皮损活检体外处理和临床试验应答者活检均显示炎症通路下调及IL1B、CXCL1、CXCL8等基因抑制。提示特异性抑制SIK2/SIK3可减少银屑病的急性期免疫和中性粒细胞募集。

要点

  • 银屑病皮损中SIK2和SIK3表达丰富,SIK1不表达。
  • GLPG3970在免疫细胞和成纤维细胞中降低TNF、IFNγ、IL-1β、IL-6、CXCL8、CXCL10。
  • GLPG3970对培养的角质形成细胞无上述细胞因子降低作用。

核心结论

  • 特异性抑制SIK2/SIK3可减少银屑病的急性期免疫和中性粒细胞募集。

研究设计与样本

  • 使用空间转录组学和单细胞测序分析银屑病皮损中SIK1/2/3的表达。
  • 体外用GLPG3970处理外周单个核细胞、T细胞、成纤维细胞和角质形成细胞并检测细胞因子/趋化因子。
  • 对银屑病皮损活检进行体外GLPG3970处理,并对临床试验中应答者与安慰剂治疗患者的活检进行批量RNA测序。

主要发现

  • 银屑病皮肤中SIK2和SIK3表达丰富,SIK1不表达。
  • GLPG3970降低外周单个核细胞、T细胞和成纤维细胞中的TNF、IFNγ、IL-1β、IL-6、CXCL8、CXCL10,但不降低角质形成细胞中的这些因子。
  • 体外处理皮损活检和临床试验应答者活检均显示炎症通路下调,IL1B、CXCL1、CXCL8、CEBPB、CD177和CLEC5A受抑制。

临床怎么用

  • SIK2/SIK3抑制可能作为银屑病新治疗策略,尤其针对急性期免疫和中性粒细胞相关炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Psoriasis is a highly prevalent inflammatory skin disease for which good systemic therapeutic agents are available. However, there is still a great need for new treatment options, especially oral ones. Salt-inducible kinases (SIKs) are emerging as new druggable targets in immune diseases, and the SIK2/SIK3 inhibitor GLPG3970 recently proved to efficiently reduce psoriasis lesions in a phase Ib trial. This study assesses the molecular events underlying the beneficial effects of SIK2/SIK3 inhibition through GLPG3970 in psoriasis. Using spatial transcriptomics and single-cell sequencing, abundant expression of SIK2 and SIK3 but not of SIK1 was observed in psoriatic skin. In vitro, GLPG3970 reduced psoriasis marker cytokines and chemokines (TNF, IFNγ, IL-1β, IL-6, CXCL8, CXCL10) in peripheral mononuclear cells, T cells, and fibroblasts but not in keratinocytes. Bulk RNA sequencing of lesional psoriasis biopsies treated ex vivo with GLPG3970 and of biopsies received from responders versus placebo-treated patients from the clinical trial showed downregulation of inflammatory pathways with suppression of IL1B, CXCL1, CXCL8, CEBPB, CD177, and CLEC5A in both settings. In summary, this study suggests that specific inhibition of SIK2/SIK3 reduces acute-phase immunity and neutrophil recruitment in psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Pilz AC, Briem E, Colli M, et al. Inhibition of salt-inducible kinases 2 and 3 reduces inflammatory signature in psoriasis. J Invest Dermatol. 2026. PMID: 42612789. doi:10.1016/j.jid.2026.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。